| Distinct roles of type I and type III interferons in intestinal immunity to homologous and heterologous rotavirus infections JD Lin, N Feng, A Sen, M Balan, HC Tseng, C McElrath, SV Smirnov, ... PLoS pathogens 12 (4), e1005600, 2016 | 171 | 2016 |
| Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression M Balan, EM y Teran, AM Waaga-Gasser, M Gasser, TK Choueiri, ... Journal of Biological Chemistry 290 (13), 8110-8120, 2015 | 149 | 2015 |
| Antitumor activity of type I and type III interferons in BNL hepatoma model W Abushahba, M Balan, I Castaneda, Y Yuan, K Reuhl, E Raveche, ... Cancer Immunology, Immunotherapy 59, 1059-1071, 2010 | 129 | 2010 |
| Regulation of apoptosis by type III interferons W Li, A Lewis‐Antes, J Huang, M Balan, SV Kotenko Cell proliferation 41 (6), 960-979, 2008 | 118 | 2008 |
| Interferon lambda: a new sword in cancer immunotherapy A Lasfar, W Abushahba, M Balan, KA Cohen-Solal Journal of Immunology Research 2011, 2011 | 109 | 2011 |
| Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus J Huang, SV Smirnov, A Lewis-Antes, M Balan, W Li, S Tang, GV Silke, ... Proceedings of the National Academy of Sciences 104 (23), 9822-9827, 2007 | 78 | 2007 |
| Brain injury expands the numbers of neural stem cells and progenitors in the SVZ by enhancing their responsiveness to EGF D Alagappan, DA Lazzarino, RJ Felling, M Balan, SV Kotenko, ... Asn Neuro 1 (2), AN20090002, 2009 | 77 | 2009 |
| Metabolic reprogramming in renal cancer: events of a metabolic disease S Chakraborty, M Balan, A Sabarwal, TK Choueiri, S Pal Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1876 (1), 188559, 2021 | 71 | 2021 |
| Mier y Teran E, Waaga-Gasser AM, Gasser M, Choueiri TK M Balan Freeman G, Pal S. Novel roles of c-Met in the survival of renal cancer cells …, 2015 | 66 | 2015 |
| Murine models of chronic lymphocytic leukaemia: role of microRNA‐16 in the New Zealand Black mouse model BJ Scaglione, E Salerno, M Balan, F Coffman, P Landgraf, F Abbasi, ... British journal of haematology 139 (5), 645-657, 2007 | 64 | 2007 |
| A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation M Balan, S Pal Journal of Biological Chemistry 289 (6), 3126-3137, 2014 | 62 | 2014 |
| Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1 S Chakraborty, M Balan, E Flynn, D Zurakowski, TK Choueiri, S Pal Oncogenesis 8 (2), 7, 2019 | 48 | 2019 |
| Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth M Balan, S Chakraborty, E Flynn, D Zurakowski, S Pal Scientific Reports 7 (1), 5900, 2017 | 37 | 2017 |
| High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting D Medvetz, Y Sun, C Li, D Khabibullin, M Balan, A Parkhitko, C Priolo, ... Molecular Cancer Research 13 (1), 50-62, 2015 | 33 | 2015 |
| Egr-1 is a critical regulator of EGF-receptor-mediated expansion of subventricular zone neural stem cells and progenitors during recovery from hypoxia–hypoglycemia D Alagappan, M Balan, Y Jiang, RB Cohen, SV Kotenko, SW Levison ASN neuro 5 (3), AN20120032, 2013 | 25 | 2013 |
| A novel combination treatment with Honokiol and Rapamycin effectively restricts c-Met-induced growth of renal cancer cells, and also inhibits the expression of tumor Cell PD-L1 … A Sabarwal, S Chakraborty, S Mahanta, S Banerjee, M Balan, S Pal Cancers 12 (7), 1782, 2020 | 14 | 2020 |
| Novel Honokiol-eluting PLGA-based scaffold effectively restricts the growth of renal cancer cells Y Hamedani, S Chakraborty, A Sabarwal, S Pal, S Bhowmick, M Balan PLoS One 15 (12), e0243837, 2020 | 11 | 2020 |
| Correction: distinct roles of type I and type III interferons in intestinal immunity to homologous and heterologous rotavirus infections JD Lin, N Feng, A Sen, M Balan, HC Tseng, C McElrath, SV Smirnov, ... PLoS pathogens 12 (6), e1005726, 2016 | 10 | 2016 |
| Tumor Microenvironment and Resistance to Current Therapies A Lasfar, M Balan, KA Cohen-Solal, A Zloza Frontiers in Oncology 9, 1131, 2019 | 8 | 2019 |
| A combination therapy using an mTOR inhibitor and honokiol effectively induces autophagy through the modulation of AXL and rubicon in renal cancer cells and restricts renal … A Sabarwal, J Wedel, K Liu, D Zurakowski, S Chakraborty, E Flynn, ... Carcinogenesis 43 (4), 360-370, 2022 | 7 | 2022 |
